Back to Search Start Over

Association Between Cyclooxygenase-2 Expression in Atypical Hyperplasia and Risk of Breast Cancer

Authors :
Wilma L. Lingle
Ari Ristimäki
Marta Santisteban
Robert A. Vierkant
V. Shane Pankratz
Daniel W. Visscher
Marlene H. Frost
Lynn C. Hartmann
Carol Reynolds
Source :
JNCI Journal of the National Cancer Institute. 100:421-427
Publication Year :
2008
Publisher :
Oxford University Press (OUP), 2008.

Abstract

The cyclooxygenase-2 (COX-2) enzyme, which is induced by inflammatory and mitogenic stimuli, plays a protumorigenic role in several human cancers. COX-2 is overexpressed in invasive and in situ breast cancers. Atypical hyperplasia in breast tissue, although benign, is associated with a high risk of breast cancer. We investigated whether COX-2 overexpression in atypical hyperplasia is associated with the risk of subsequent breast cancer.COX-2 expression was assessed immunohistochemically in archival sections from 235 women with atypia whose biopsy specimens were obtained at the Mayo Clinic from January 1, 1967, through December 31, 1991. COX-2 expression was scored as 0 (negative), 1+ (weak), 2+ (moderate), or 3+ (strong). Risk factor information and follow-up for breast cancer events were obtained via a study questionnaire and the medical records. All statistical tests were two-sided.Forty-one (17%) of the 235 women developed breast cancer during a median follow-up of 15 years. Moderate (category 2+) or strong (category 3+) COX-2 expression was identified in 71 (30%) and 34 (14%) of the 235 samples, respectively. The risk for developing breast cancer, relative to a control population (the Iowa Surveillance, Epidemiology, and End Results registry), increased with increasing COX-2 expression (relative risk [RR] = 2.63, 95% confidence interval [CI] = 1.56 to 4.15, for those with negative or weak COX-2 expression; RR = 3.56, 95% CI = 1.94 to 5.97, for those with moderate expression; and RR = 5.66, 95% CI = 2.59 to 10.75, for those with strong expression; P = .07). Overexpression of COX-2 was statistically significantly associated with the type of atypia (lobular vs ductal, P.001), number of foci of atypia in the biopsy (P = .02), and older age at time of biopsy (45 years, P = .01).COX-2 appears to be a biomarker that further stratifies breast cancer risk among women with atypia and may be a relevant target for chemoprevention strategies.

Details

ISSN :
14602105 and 00278874
Volume :
100
Database :
OpenAIRE
Journal :
JNCI Journal of the National Cancer Institute
Accession number :
edsair.doi.dedup.....3713a2ba3dfc7eb65f029368665fc9a6